|
Synonyms: AR-320 | MEDI4893
Compound class:
Antibody
Comment: Suvratoxumab is a clinical stage fully human IgG1 monoclonal antibody that prevents binding of Staphylococcus aureus alpha-toxin to its cellular receptor ADAM10 [2]. It is being developed for the prevention of nocosomial pneumonia caused by S. aureus.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. |
| No information available. |
Summary of Clinical Use  |
| Suvratoxumab is under clinical evaluation as a preventative treatment for patients at risk of ventilator-associated bacterial pneumonia (VAP) caused by S. aureus. Phase 2 (NCT02296320) results have been published [1] and although this study failed to meet its primary endpoint it did support the need for further larger studies with a Phase 3 (NCT05331885) now recruiting. Suvratoxumab has been granted Fast Track designation by the US FDA. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05331885 | A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2 | Phase 3 Interventional | Aridis Pharmaceuticals, Inc. | ||
| NCT02296320 | Study of the Efficacy and Safety of MEDI4893 | Phase 2 Interventional | MedImmune LLC | 1 | |
